



Editor

Josef S Smolen

Associate Editors

Francis Berenbaum
 Dimitrios Boumpas
 Gerd Burmester
 Mary Crow
 Iain McInnes
 Thomas Pap
 David Pisetsky
 Désirée van der Heijde
 Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
 BMJ Publishing Group Ltd
 BMA House
 Tavistock Square
 London WC1H 9JR, UK
 T: +44 (0)20 3655 5889
 E: ard@bmj.com
 Twitter: @ARD_BMJ
 ISSN: 0003-4967 (print)
 ISSN: 1468-2060 (online)

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2019 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorials

1449 Shared genetic factors and their causality in autoimmune diseases
K Yamamoto, Y Okada

1452 Getting to the heart of the matter: detecting and managing cardiac complications in systemic sclerosis
J Varga, D C Lee

Rheumatoid arthritis

1454 Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
R M Fleischmann, M C Genovese, J V Enejsa, E Mysler, L Bessette, C Peterfy, P Durez, A Ostor, Y Li, I-H Song

1463 Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017
S Safiri, A A Kolahi, D Hoy, E Smith, D Bettampadi, M A Mansournia, A Almasi-Hashiani, A Ashrafi-Asgarabad, M Moradi-Lakeh, M Qorbani, G Collins, A D Woolf, L March, M Cross

1472 Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries
P Putrik, S Ramiro, F Guillemin, M Péntek, F Sivera, T Sokka, M de Wit, A D Woolf, A Zink, D Andersone, F Berghea, I Butrimiene, S Brouwer, K Cassar, P Charalambous, R Caporali, E Deseaticova, N S Damjanov, A Finckh, O FitzGerald, G Gröndal, N Gobejishvili, P Gluszek, M Hirsch, I Jovanovic, J Vencovsky, X Janssens, A P Keszei, M Kovarova, M Kull, L Cunha Miranda, M Mayer, S Misevska - Percinkova, N Inanc, O Nadashkevich, I F Petersson, K Puolakka, B Rojkovich, H Radner, F Szabados, G Slobodin, I Shirinsky, N Soroka, P Sidiropoulos, R Shumnalieva, S Sokolovic, S Shukurova, A Tafaj, M Tomšič, T Uhlig, S M M Verstappen, A Boonen

1480 Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor
Y Ishikawa, K Ikari, M Hashimoto, K Ohmura, M Tanaka, H Iio, A Taniguchi, H Yamanaka, T Mimori, C Terao

1488 Potential involvement of OX40 in the regulation of autoantibody sialylation in arthritis
I Kurata, I Matsumoto, A Ohyama, A Osada, H Ebe, H Kawaguchi, S Kaneko, Y Kondo, H Tsuboi, A Tomioka, H Kajii, T Sumida

1497 Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status
D M Boeters, L E Burgers, R EM Toes, A van der Helm-van Mil

1505 Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis
J Rodríguez-Ubreva, C de la Calle-Fabregat, T Li, L Ciudad, M L Ballestar, F Català-Moll, O Morante-Palacios, A Garcia-Gomez, R Celis, F Humby, A Nerviani, J Martin, C Pitzalis, J D Cañete, E Ballestar

Psoriatic arthritis

1517 Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark
J Guldberg-Møller, R L Cordtz, L E Kristensen, L Dreyer

Inflammatory arthritis

1524 Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis
R Liu, Y Chen, W Fu, S Wang, Y Cui, X Zhao, Z-N Lei, A Hetinghouse, J Liu, C Wang, C Zhang, Y Bi, G Xiao, Z-S Chen, C Liu

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008

JMK0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

Spondyloarthritis

- 1536** Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
L M Ørnbjerg, C H Brahe, J Askeling, A Ciurea, H Mann, F Onen, E K Kristianslund, D Nordström, M J Santos, C Codreanu, J Gómez-Reino, Z Rotar, B Gudbjornsson, D Di Giuseppe, M J Nissen, K Pavelka, M Birklik, T Kvien, K K Eklund, A Barcelos, R Ionescu, C Sanchez-Piedra, M Tomsic, Á J Geirsson, A G Loft, I van der Horst-Bruinsma, G Jones, F Iannone, L Hylndstrup, N S Krogh, M L Hetland, M Østergaard
- 1545** Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts
A Boel, A Molto, D van der Heijde, A Ciurea, M Dougados, L S Gensler, M-J Santos, E De Miguel, D Poddubnyy, M Rudwaleit, A van Tubergen, F A van Gaalen, S Ramiro
- 1550** MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group
W P Maksymowych, R GW Lambert, M Østergaard, S J Pedersen, P M Machado, U Weber, A N Bennett, J Braun, R Burgos-Vargas, M de Hooge, A A Deodhar, I Eshed, A G Jurik, K-G A Hermann, R BM Landewé, H Marzo-Ortega, V Navarro-Compán, D Poddubnyy, M Reijnen, M Rudwaleit, J Sieper, F E Van den Bosch, D van der Heijde, I E van der Horst-Bruinsma, S Wichuk, X Baraliakos
- 1559** Evidence that tissue resident human enthesis $\gamma\delta$ T-cells can produce IL-17A independently of IL-23R transcript expression
R J Cuthbert, A Watad, E M Fragkakis, R Dunsmuir, P Loughenbury, A Khan, P A Millner, A Davison, H Marzo-Ortega, D Newton, C Bridgewood, D G McGonagle
- 1566** Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis
Z Qaiyum, E Gracey, YC Yao, R D Inman

Systemic sclerosis

- 1576** Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study
G Valentini, D Huscher, A Riccardi, S Fasano, R Irace, V Messinuti, M Matucci-Cerinic, S Guiducci, O Distler, B Maurer, J Avouac, I H Turner, M Frerix, G Riemekasten, E Siegert, L Czirájk, V Lóránd, C P Denton, S Nihtyanova, U A Walker, V K Jaeger, F Del Galdo, G Abignano, L P Ananieva, A M Gherghe, C Mihai, J C Henes, T Schmeiser, A Vacca, S Moiseev, I Foeldvari, A Gabrielli, B Krummel-Lorenz, S Rednic, Y Allano, U Müller-Ladner
- 1583** Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis
M Wu, B Skaug, X Bi, T Mills, G Salazar, X Zhou, J Reville, S K Agarwal, M R Blackburn, M D Mayes, S Assassi

Crystal arthropathies

- 1592** Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
D Bursill, W J Taylor, R Terkeltaub, A Abhishek, A K So, A B Vargas-Santos, A L Gaffo, A Rosenthal, A-K Tausche, A Reginato, B Manger, C Sciré, C Pineda, C van Durme, C-T Lin, C Yin, D A Albert, E Biernat-Kaluza, E Roddy, E Pascual, F Becce, F Perez-Ruiz, F Sivera, F Lioté, G Schett, G Nuki, G Filippou, G McCarthy, G da Rocha Castelar Pinheiro, H-K Ea, H D A Tupinambá, H Yamanaka, H K Choi, J Mackay, J R ODell, J Vázquez Mellado, J A Singh, J D Fitzgerald, L T H Jacobsson, L Joosten, L R Harrold, L Stamp, M Andrés, M Gutierrez, M Kuwabara, M Dehlin, M Janssen, M Doherty, M S Hershfield, M Pillinger, N L Edwards, N Schlesinger, N Kumar, O Slot, S Ottaviani, P Richette, P A MacMullan, P T Chapman, P E Lipsky, P Robinson, P P Khanna, R N Gancheva, R Grainger, R J Johnson, R Te Kampe, R T Keenan, S K Tedeschi, S Kim, S J Choi, T R Fields, T Bardin, T Uhlig, T Jansen, T Merriman, T Pascart, T Neogi, V Klüick, W Louthrenoo, N Dalbeth
- 1601** Risk of gout flares after vaccination: a prospective case cross-over study
C Yokose, N McCormick, C Chen, T Neogi, C Chaisson, R Terkeltaub, D J Hunter, Y Zhang, H Choi

Letters

- 1605** Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study
M de Hooge, F A van Gaalen, T Renson, A-S De Craemer, M G van de Sande, R Ramonda, K M Fagerli, L T H Jacobsson, D van der Heijde, D Elewaut, F Van den Bosch
- 1606** Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib
M Levraut, N Martis, P Viau, F Suarez, V Queyrel
- 1607** Patient and public involvement in biomedical research: training is not a substitute for relationship building
A G Wilson, J Sherwin, E R Dorris

Electronic pages

- e119** Clinical evidence guidelines in systemic lupus erythematosus: revaluation
M Scheinberg
- e120** Response to: 'Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg
B A Pons-Estel, E Bonfá, E R Soriano, M H Cardiel, A Izcovich, G Vázquez, G S Alarcón
- e121** Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand *et al*
D Isenberg
- e122** Response to: 'Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand *et al*
by Isenberg
E F Morand, T Trasieva, A Berglind, G Illei, R Tummala
- e123** Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series
J Narváez, J LLuch, J J Alegre Sancho, M Molina-Molina, J M Nolla, I Castellví
- e124** Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez
D Khanna, A Jahreis, C J F Lin
- e125** Will SPAR be useful in the usual patients with scleroderma?
A Chattopadhyay, V Dhir, S Sharma, A Sharma, S Jain
- e126** Response to: 'Will SPAR be useful in the usual patients with scleroderma?' by Chattopadhyay *et al*
W Wu, S Jordan, O Distler
- e127** M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis
A Lescoat, A Ballerie, S Jouneau, O Fardel, L Vernhet, P Jego, V Lecreur
- e128** Monocyte and macrophage phenotypes: a look beyond systemic sclerosis. Response to: 'M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis' by Lescoat *et al*
M Cutolo, A C Trombetta, S Soldano
- e129** Immune checkpoint inhibitor rechallenge in patients with immune-related myositis
J Delyon, F Brunet-Possenti, S Leonard-Louis, D Arangalage, M Baudet, B Baroudjian, C Lebbe, B Hervier, on behalf of the PATIO Group
- e130** Coffee consumption and gout: a Mendelian randomisation study
Y H Lee